Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18558250 | 0.91 | MAPT (0.48) | ROCK2ROCK1P2RX7EPHX2MAPT | |
| SCHEMBL18558668 | 0.91 | P2RX7 (0.47) | ROCK2ROCK1P2RX7 | |
| SCHEMBL9905224 | 0.87 | P2RX7 (0.43) | ROCK2ROCK1P2RX7 | |
| SCHEMBL9905225 | 0.87 | P2RX7 (0.43) | ROCK2ROCK1P2RX7 | |
| SCHEMBL18558571 | 0.87 | P2RX7 (0.45) | ROCK2ROCK1P2RX7 | |
| SCHEMBL18558586 | 0.87 | P2RX7 (0.45) | ROCK2ROCK1P2RX7 | |
| SCHEMBL18557578 | 0.86 | ROCK2 (0.45) | ROCK2ROCK1P2RX7 | |
| SCHEMBL18558144 | 0.85 | P2RX7 (0.45) | ROCK2ROCK1P2RX7 | |
| SCHEMBL18558567 | 0.83 | MAPT (0.45) | ROCK2ROCK1P2RX7EPHX2MAPT | |
| SCHEMBL19362800 | 0.83 | MAPT (0.43) | ROCK2ROCK1P2RX7EPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932313-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-09-21 | — | — | US | disclosed |
| US-9580388-B2 | Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267643-A1 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5F1D, ATP5ME | ROCK2 1467/4885ROCK1 849/4885P2RX7 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.